1/47
Vocabulary practice cards defining key enzymes, regulatory factors, transport proteins, pathways, and clinical conditions in metabolic biochemistry (lipid, amino acid, heme, one-carbon, and nucleotide metabolism).
Triglycerides (TAGs)
Primary energy storage molecules in adipose tissue yielding approximately 9kcal/g, composed of a glycerol backbone esterified to three fatty acid chains via ester linkages, and functioning in thermal insulation and organ cushioning.
Pancreatic Lipase
An enzyme secreted into the intestinal lumen that hydrolyzes dietary triglycerides at the sn-1 and sn-3 positions (assisted by colipase) to yield 2-monoglycerides (2-MAG) and free fatty acids (FFAs).
Lipoprotein Lipase (LPL)
An enzyme anchored to capillary endothelium in adipose and skeletal or cardiac muscle that is activated by ApoC-II to hydrolyze triglycerides inside circulating chylomicrons and VLDL into free fatty acids and glycerol.
Adipose Triglyceride Lipase (ATGL)
The rate-limiting enzyme of the adipocyte intracellular lipolysis cascade that converts triglycerides to diacylglycerol (DAG) and one free fatty acid; it is transcriptionally regulated by PPARγ and directly activated by the cofactor CGI-58.
Hormone-Sensitive Lipase (HSL)
An adipocyte enzyme that converts diacylglycerol (DAG) to monoacylglycerol (MAG) and one free fatty acid; it is activated by PKA-dependent phosphorylation (stimulated by catecholamines, glucagon, and ACTH) and inactivated via dephosphorylation stimulated by insulin.
Monoglyceride Lipase (MGL)
The terminal enzyme of the intracellular adipocyte lipolysis cascade that cleaves monoacylglycerol (MAG) into glycerol and one free fatty acid.
HMG-CoA Reductase
The rate-limiting enzyme of cholesterol biosynthesis located in the cytoplasm/ER that converts HMG-CoA to mevalonate; it is transcriptionally upregulated by SREBP2, activated via dephosphorylation by insulin, and inhibited via phosphorylation by AMPK or glucagon.
SREBP2 (Sterol Regulatory Element-Binding Protein 2)
A sterol-sensing transcription factor that is escorted by SCAP from the ER to the Golgi when intracellular sterols are low, where it undergoes proteolytic cleavage so its active N-terminal domain can enter the nucleus and bind sterol regulatory elements (SREs) to upregulate transcription of HMG-CoA reductase and the LDL receptor.
LCAT (Lecithin:Cholesterol Acyltransferase)
A plasma enzyme bound to HDL that is activated by ApoA-I to transfer a fatty acid from phosphatidylcholine (lecithin) to free cholesterol, generating hydrophobic cholesteryl esters for reverse cholesterol transport.
ACAT (Acyl-CoA:Cholesterol Acyltransferase)
An intracellular enzyme that synthesizes cholesteryl esters from free cholesterol and fatty acyl-CoA for intracellular lipid droplet storage.
Cholesterol 7α-Hydroxylase (CYP7A1)
The rate-limiting microsomal enzyme in the synthesis of primary bile acids (cholic acid and chenodeoxycholic acid) from cholesterol, serving as the primary pathway for cholesterol excretion.
Statins
A class of competitive inhibitors of HMG-CoA reductase (e.g., lovastatin, atorvastatin) structured to mimic the HMG-CoA/mevalonate transition state, thereby depleting hepatocyte cholesterol and triggering SREBP2-mediated upregulation of cell-surface LDL receptors to enhance plasma LDL-C clearance.
Chylomicrons
The lowest-density (<0.95g/mL) lipoproteins synthesized by enterocytes, containing approximately 90% dietary triglycerides along with apoproteins B-48, A-I, C-II, and E, which transport dietary lipids to peripheral tissues.
VLDL (Very Low-Density Lipoprotein)
A liver-derived lipoprotein (density 0.95–1.006g/mL) consisting of approximately 60% endogenous triglycerides and apoproteins B-100, C-II, and E that transports liver-synthesized triglycerides to peripheral tissues.
IDL (Intermediate-Density Lipoprotein)
A transient lipoprotein remnant of VLDL metabolism (density 1.006–1.019g/mL) enriched in triglycerides and cholesteryl esters and bearing apoproteins B-100 and E, which is either cleared directly by the liver or converted by hepatic lipase into LDL.
LDL (Low-Density Lipoprotein)
A cholesterol-rich lipoprotein (density 1.019–1.063g/mL) composed of approximately 50% cholesteryl esters and apoprotein B-100 that delivers cholesterol to peripheral tissues and the liver via receptor-mediated endocytosis.
HDL (High-Density Lipoprotein)
The highest-density (1.063–1.210g/mL) lipoprotein composed of phospholipids, cholesteryl esters, and approximately 50% protein (carrying A-I, A-II, C, and E apoproteins), which mediates reverse cholesterol transport and acts as a circulating apoprotein reservoir.
ApoC-II
An exchangeable apoprotein transferred from HDL to chylomicrons and VLDL that acts as the essential cofactor required to activate lipoprotein lipase (LPL) on capillary endothelium.
ApoE
An apoprotein present on chylomicrons, VLDL, IDL, and HDL that mediates high-affinity binding to hepatic remnant receptors to trigger endocytic clearance of lipoprotein remnants by the liver.
PCSK9
A regulatory protein that binds cell-surface LDL receptors and targets them for lysosomal degradation rather than allowing endosomal recycling back to the plasma membrane.
Familial Hypercholesterolemia (FH)
An autosomal dominant disorder caused primarily by loss-of-function mutations in the LDLR gene (or mutations in APOB or gain-of-function PCSK9), resulting in impaired clearance of plasma LDL-C, xanthomas, corneal arcus, and premature atherosclerosis via macrophage foam cell formation.
Nitrogen Balance
The physiological relationship between nitrogen intake and excretion, categorized as equilibrium in healthy adults, positive (intake exceeding excretion) during growth, pregnancy, and recovery, or negative (excretion exceeding intake) during starvation, burns, trauma, or sepsis.
Pyridoxal Phosphate (PLP)
The active coenzyme form of vitamin B6 that forms a Schiff base intermediate with amino acids to transiently hold amino groups as pyridoxamine phosphate (PMP) during aminotransferase-catalyzed transamination reactions.
Carbamoyl Phosphate Synthetase I (CPS-I)
The rate-limiting mitochondrial enzyme of the urea cycle that condenses free NH4+, HCO3−, and 2ATP into carbamoyl phosphate; it requires N-acetylglutamate (NAG) as an obligatory allosteric activator.
N-Acetylglutamate (NAG)
An obligatory short-term allosteric activator of carbamoyl phosphate synthetase I (CPS-I), synthesized by NAG synthase in response to elevated arginine, glutamate, and acetyl-CoA concentrations.
Ornithine Transcarbamoylase (OTC)
A mitochondrial urea cycle enzyme that condenses carbamoyl phosphate with ornithine to synthesize citrulline, which is subsequently transported into the cytosol.
Glutamate Dehydrogenase
A mitochondrial enzyme in the liver and kidney that catalyzes the oxidative deamination of glutamate to regenerate α-ketoglutarate and release free NH4+ using NAD+ (or amination using NADPH); it is inhibited by ATP/GTP and activated by ADP/GDP.
Transdeamination
The coupled metabolic pathway wherein transamination transfers α-amino groups from various amino acids to α-ketoglutarate to form glutamate, followed by oxidative deamination of glutamate to release free ammonia for urea synthesis.
S-Adenosylmethionine (SAM)
The universal activated methyl donor formed from methionine and ATP, which is converted into S-adenosylhomocysteine (SAH) upon transfer of its methyl group during biological transmethylation reactions.
Phenylketonuria (PKU)
An inherited amino acid disorder caused by a deficiency in phenylalanine hydroxylase (or its tetrahydrobiopterin coenzyme, BH4), leading to accumulation of phenylalanine and phenylketones, intellectual disability if untreated, hypopigmentation, and a characteristic musty body odor.
Maple Syrup Urine Disease (MSUD)
An inborn error of metabolism caused by a deficiency in the branched-chain α-ketoacid dehydrogenase complex, leading to neurotoxic accumulation of leucine, isoleucine, valine, and their respective α-ketoacids, presenting with poor feeding, encephalopathy, and a burnt-sugar urine odor.
Homocystinuria
An inherited metabolic disorder caused by deficiency of cystathionine β-synthase, resulting in the accumulation of homocysteine and methionine, and characterized by thromboembolism, downward lens dislocation (ectopia lentis), and a marfanoid habitus.
Alkaptonuria
An inborn error of amino acid metabolism caused by deficiency of homogentisate 1,2-dioxygenase, causing accumulation of homogentisic acid, urine that darkens to black upon standing, ochronosis (blue-black cartilage pigmentation), and severe debilitating arthritis.
ALA Synthase (ALAS)
The committed and rate-limiting mitochondrial enzyme of heme biosynthesis that condenses glycine and succinyl-CoA into 5-aminolevulinic acid using PLP; it exists as hepatic housekeeping ALAS1 (feedback-repressed by heme/hemin) and erythroid-specific ALAS2 (regulated by iron availability).
UDP-Glucuronosyltransferase (UGT1A1)
A microsomal hepatocyte enzyme that conjugates two glucuronic acid molecules to hydrophobic unconjugated bilirubin, converting it to water-soluble bilirubin diglucuronide (direct conjugated bilirubin) for biliary secretion.
Porphyrias
A group of inherited disorders caused by partial deficiencies in enzymes of the heme biosynthetic pathway, in which accumulation of early non-cyclic intermediates (e.g., ALA, PBG) produces neurovisceral symptoms and accumulation of later porphyrinogens produces cutaneous photosensitivity.
Tetrahydrofolate (THF / FH4)
The metabolically active, fully reduced coenzyme form of folate synthesized by dihydrofolate reductase (DHFR), which acts as an essential carrier of one-carbon units at multiple oxidation states attached to N5, N10, or both.
Thymidylate Synthase
An enzyme that catalyzes the transfer and reduction of a one-carbon unit from N5,N10-methylene-THF to dUMP to form dTMP, while oxidizing THF to dihydrofolate (FH2).
Folate Trap
A functional folate deficiency resulting from vitamin B12 deficiency, wherein inability of methionine synthase to transfer the methyl group from N5-methyl-THF causes irreversible accumulation and trapping of folate as N5-methyl-THF, impairing purine and dTMP synthesis.
Methotrexate (MTX)
A synthetic folate analog and antimetabolite drug that competitively inhibits human dihydrofolate reductase (DHFR), depleting FH4 and halting dTMP and purine synthesis in rapidly dividing cells.
5-Fluorouracil (5-FU)
A pyrimidine antimetabolite drug metabolized into FdUMP, which acts as an irreversible suicide inhibitor of thymidylate synthase, depleting dTMP pools and blocking DNA replication.
Glutamine Phosphoribosyl Amidotransferase
The committed-step enzyme of de novo purine nucleotide synthesis that reacts PRPP with glutamine to form 5′-phosphoribosyl 1’-amine; it is synergistically feedback-inhibited by AMP and GMP.
HGPRT (Hypoxanthine-Guanine Phosphoribosyltransferase)
A key purine salvage enzyme that transfers a phosphoribosyl group from PRPP to hypoxanthine or guanine to reform IMP or GMP, respectively.
Carbamoyl Phosphate Synthetase II (CPS-II)
The cytosolic, committed-step enzyme of pyrimidine de novo synthesis that condenses glutamine, CO2, and 2ATP to form carbamoyl phosphate; it is allosterically inhibited by UTP and activated by PRPP and ATP.
Ribonucleotide Reductase (RR)
An enzyme that reduces ribonucleoside diphosphates (NDPs: ADP, GDP, CDP, UDP) directly into deoxyribonucleoside diphosphates (dNDPs) at the 2′ carbon using the redox protein cofactor thioredoxin.
Xanthine Oxidase
An enzyme in purine catabolism that sequentially oxidizes hypoxanthine to xanthine, and xanthine to uric acid, the poorly soluble final excretory product of purine degradation in humans.
Lesch-Nyhan Syndrome
An X-linked recessive disorder caused by complete deficiency of HGPRT, resulting in purine salvage failure, accumulation of intracellular PRPP, hyperuricemia/gout, dystonia, intellectual disability, and compulsive self-mutilation.
Allopurinol
A structural hypoxanthine analog that inhibits xanthine oxidase (metabolized to the suicide inhibitor oxypurinol/alloxanthine), reducing uric acid production while increasing the excretion of more soluble hypoxanthine and xanthine.